Information Provided By:
Fly News Breaks for October 4, 2016
ACOR
Oct 4, 2016 | 07:20 EDT
Leerink analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Market Perform rating and $25 price target.
News For ACOR From the Last 2 Days
There are no results for your query ACOR